Table 1.

Demographic and health-related characteristics at baseline, among treatment-compliant men in the Prostate Cancer Prevention Trial finasteride arm

Control (n = 694)Case (n = 553)
Mean (SD)Mean (SD)P value
Age, ya63.8 (5.6)64.1 (5.7)0.35
Body mass index, kg/m227.7 (4.1)27.4 (3.8)0.30
Prostate specific antigen, ng/mL1.2 (0.7)1.6 (0.7)<0.0001
Cholesterol, mg/dL216.6 (37.9)216.7 (41.1)
N (%)N (%)
Family history of prostate cancera148 (21.3)127 (23.0)0.49
Diabetes51 (7.3)32 (5.8)0.27
Race
Non-Hispanic White514 (74.1)512 (92.6)<0.0001
African-Americanb93 (13.4)29 (5.2)
Other87 (12.5)12 (2.2)
Education, y
≤12146 (21.1)96 (17.4)0.01
13–15217 (31.3)146 (26.4)
≥16+330 (47.6)311 (56.2)
Smoking
Never244 (35.2)193 (34.9)0.12
Current58 (8.4)30 (5.4)
Former392 (56.5)330 (59.7)
Alcohol intake, g/d
0161 (23.2)132 (23.9)0.88
>0–<30472 (68.0)369 (66.7)
≥3061 (8.8)52 (9.4)
Body mass index, kg/m2
Normal (<25)184 (26.7)146 (26.6)0.99
Overweight (25–<30)344 (50.0)277 (50.5)
Obese (≥30)160 (23.3)126 (23.0)
  • aMatching variable for control selection.

  • bNon-White controls were oversampled.